NCT01661881View on ClinicalTrials.gov

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 16, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2030

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Rituximab

DRUG

Bendamustine

DRUG

Cytarabine

Trial Locations (3)

02113

Massachusetts General Hospital, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER